Drug intelligence / Profile preview

Emcor

Development stage: Unknown
Lead developer: Emcutix Biopharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Emcor is a topical cream formulation developed and marketed by Emcutix Biopharmaceuticals, a wholly-owned subsidiary of Emcure Pharmaceuticals focused exclusively on dermatology. Launched in October 2024 as part of a differentiated product portfolio for the Indian market, Emcor is indicated for various dermatologic conditions and skincare. The product is supplied as a 2.5 mg cream in 15g tubes and is manufactured by Akums Drugs & Pharmaceuticals. While the specific active pharmaceutical ingredient and biological target are not publicly detailed in initial commercial listings, the product is part of an approved commercial line aimed at addressing unmet needs in aesthetic and medical dermatology.

Brand names: Emcor

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on Emcor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emcor.

Explore the full profile